It would not be surprising to those who have noticed the significant increase in interest in the GLP-1 phenomenon this year that this new class of drugs has become a major player in the realm of weight loss methods, at least in terms of Google searches. The Glucagon-Like Peptide-1 (GLP-1) hormone is vital in regulating hunger by stimulating insulin release in the pancreas, preventing the unhelpful release of glucagon after meals, and slowing stomach emptying to reduce overall food intake. Additionally, GLP-1 receptors suppress the brain’s stress response and reinforcement mechanism, enhancing the feeling of satiation.
Novo Nordisk markets:
Novo Nordisk markets its Semaglutide GLP-1 injections under the brand names Ozempic and Wegovy. Meanwhile, Eli Lilly and Company offers its Tripeptide GLP-1 cocktail with the Manjiro and Ze bound labels. Structure Therapeutics has recently gained attention with its orally administered GLP-1 drug combination, which has shown promising results in early trials and is considered a significant development in the weight loss field.
According to an analysis:
According to an analysis by Garage Gym Reviews, Google searches for GLP-1 weight loss drugs like Ozempic have risen 13.7 times faster than searches for traditional weight loss methods such as diet, nutrition, and exercise since Q1 2022. Meanwhile, search queries for traditional weight loss methods have decreased by 26 percent relative to Q1 2022.
Fitness programs:
Some experts anticipate that gym-goers may soon have access to GLP-1 drugs as part of their fitness programs to boost overall effectiveness. However, the fitness industry is divided on this, with some labeling it as a superficial solution to a complex obesity issue.
Estimate suggests:
Morgan Stanley’s estimate suggests that approximately 11 percent of US households, equivalent to about 5 percent of the total population, currently include at least one member using GLP-1 drugs on a weekly basis. Additionally, 17 percent of households are open to the possibility of a family member adopting this pharmaceutical intervention.
Annual sales:
According to estimates by Capital Group, the Total Addressable Market (TAM) for GLP-1 drugs exceeds 2 billion people, indicating strong potential. This supports the projection that the annual sales of these drugs will reach the $100 billion mark by 2030.
-
-
-
-
